Cost-Effectiveness Analysis of Prostate Health Index in Decision Making for Initial Prostate Biopsy.

ABSTRACT:

Background

Clinical studies have suggested that prostate health index (phi) outperforms prostate-specific antigen (PSA) tests in prostate cancer detection. The cost-effectiveness of phi with different cutoffs is poorly understood in the context of decision making for prostate biopsy.

Methods

In a multicenter cohort, 3,348 men with elevated total PSA (tPSA) underwent initial prostate biopsy from August 2013 to May 2019. We constructed a decision model to evaluate the incremental cost-effectiveness ratios of different phi cutoffs. Total costs and reimbursement payments were based on the fee schedule of Shanghai Basic Medical Insurance and converted into United States dollars ($). Two willingness-to-pay thresholds were estimated as one or three times the av

SUBMITTER: Huang D 

PROVIDER: S-EPMC7732507 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature